Translocations of the ETS transcription factors ERG, ETV1, ETV4, ETV5 and FLI1 occur in half of all prostate cancer, and the TMPRSS2-ERG translocation is the most common molecular alteration 1-4 . Evidence from human tumor analyses has strongly implicated aberrant ETS expression as an early, if not initiating, event [5] [6] [7] .
a r t i c l e s 1 0 2 4 VOLUME 19 | NUMBER 8 | AUGUST 2013 nature medicine prostates ( Fig. 2a,b) . The tumor cells uniformly expressed nuclear ERG and AR and showed AKT activation. Although the invasive regions were highly proliferative, the proliferative index of PIN lesions in Pten flox/flox ; R26 ERG prostates was only slightly higher than in Pten flox/flox prostates ( Fig. 2c ), suggesting that ERG expression within PIN does not significantly affect proliferation. Instead, ERG expression may facilitate invasion and progression, as has been suggested in earlier in vitro studies 16, 18 . Human PIN retains a basal layer of P63 (also known as TP63)-and cytokeratin 5 (CK5)-positive cells beneath a luminal layer of CK8-positive cells, whereas adenocarcinoma is characterized by irregular glandular structures that have lost the basal layer. In Pten flox/flox PIN, P63 and CK5 are maintained in the basal cells, and CK5 is ectopically expressed in some luminal cells, consistent with previous reports (Supplementary Fig. 4 ) 19 . Pten flox/flox ; R26 ERG adenocarcinoma is invariably positive for CK8 and negative for P63, consistent with human adenocarcinoma. CK5 expression is variable and, when present, coincides with CK8 expression. CK5 and CK8 double-positive cells, called 'intermediate cells' , are detectable in a subset of human prostate cancers 20 . By 12 months of age, some mice developed foci of poorly differentiated carcinoma that maintained expression of AR, ERG and CK8 and showed patchy neuroendocrine differentiation, as demonstrated by nestin staining ( Fig. 2d and Supplementary Fig. 5 ). These patterns are reminiscent of human Gleason grade 5 cancer with focal neuroendocrine differentiation, which is in contrast to 'small-cell' cancer that is characterized by loss of AR and uniform neuroendocrine staining. Pten flox/flox ; R26 ERG mice had shortened survival relative to Pten flox/flox mice ( Fig. 2e) , with early deaths due to increased abdominal girth and penile prolapse.
ERG reprograms the AR cistrome
The robust and uniform expression of ERG in R26 ERG and transcriptome under controlled conditions. Chromatin immunoprecipitation and sequencing (ChIP-seq) analysis identified 24,665 ERG peaks in prostate tissue from R26 ERG mice ( Supplementary  Table 1 ). Although the majority of the ERG peaks were located in enhancer regions, they were enriched at promoters (30% compared to 3% in the genome-wide background, P < 2.2 × 10 −16 ) ( Supplementary Fig. 6 ), which is consistent with previous ERG ChIP-seq results 21, 22 . ERG peaks were present in Dusp6, Tmprss2 and Fkbp5, whose human homologs are ERG and ETV1 target genes in ERG-positive VCAP and ETV1-positive LNCaP cells ( Fig. 3a and Supplementary Figs. 7 and 8) , giving us further confidence in the physiologic relevance of the mouse model. We observed a similar distribution of ERG binding sites in the background of Pten loss (Supplementary Figs. 9 and 10). We next examined the genome-wide localization of AR by ChIPseq. Notably, there was a greater than fourfold increase in the number of AR peaks in R26 ERG (14, 889) compared to wild-type (WT; 3,476) prostates ( Fig. 3b and Supplementary Table 1 ). The number of AR peaks was also increased in Pten flox/flox ; R26 ERG prostates, although to a lesser extent than in prostates from mice with wild-type Pten (Pten WT mice). We validated the increased AR binding at several enhancers using ChIP with quantitative PCR (ChIP-qPCR) of independent samples ( Supplementary Fig. 11 ). We confirmed that the change in the AR cistrome was not due to a difference in the amount of AR protein or circulating testosterone ( Fig. 1a and Supplementary  Figs. 12 and 13) .
De novo MEME motif analysis 23 of ERG peaks identified the ETS core consensus GGAA motif with a 5′-CC and 3′-GT bias, which is identical to human prostate cancer cells. AR motif analysis showed that pre-existing sites in WT mice and new sites in R26 ERG mice contained the identical AR motif (Supplementary Fig. 14) . To discover potential cooperating transcription factors for AR binding, we performed DREME analysis 24 . One distinguishing feature between the conserved and new AR peaks was greater enrichment for GATA motifs in the new AR peaks and forkhead box A1 (FOXA1) motifs in conserved AR peaks ( Fig. 3c and Supplementary Table 2 ). This is of potential interest because GATA2 is essential for prostate development and cooperates with AR to modulate gene expression 25, 26 .
The percentage of AR and ERG peaks that physically colocalized in R26 ERG mouse prostates was ~44% ( Fig. 3d) , which is highly significant (P < 1 × 10 −20 ) and comparable to that in VCAP cells. Yet new AR peaks had less overlap with ERG peaks than did the conserved AR peaks (~40% compared to ~60%; Fig. 3e,f) , making it unlikely that ERG directly recruits AR to new sites. However, a large fraction of new AR sites (77%, P < 1 × 10 −20 ) mapped to genes containing ERG sites, raising the possibility of an ERG-mediated field effect that promotes AR binding, perhaps by functioning as a pioneer factor. Several classes of pioneer factors have been defined. One class, exemplified by the ETS factor PU.1 (also known as SPI1), binds to closed chromatin regions and generates de novo enhancers that are characterized by histone H3 Lys4 methylation (H3K4me1), which in turn guide recruitment of other transcription factors 27, 28 . Another class, exemplified by FOXA1, binds to pre-established H3K4me1 enhancer regions and instructs the binding of additional transcriptional factors (for example, AR) to both adjacent and distant pre-existing enhancer regions 25, 29, 30 . To determine whether ERG resembles one of these classes of pioneer factors, we examined the distribution of H3K4me1. The collective distribution of H3K4me1 around ERG binding sites was similar between WT and R26 ERG prostates, suggesting that ERG binds to pre-existing enhancers ( Fig. 3g) . Further, the collective distributions of H3K4me1 around both conserved and new AR peaks were similar between WT and R26 ERG prostates, suggesting that ERG expression helps guide AR to pre-existing enhancers (Fig. 3h) . Notably, the normalized H3K4me1 ChIP signal was consistently slightly higher in R26 ERG mice for all three types of peaks (ERG, new AR and conserved AR), raising the possibility that ERG may strengthen pre-existing enhancers. Collectively these data support a model in which ERG reprograms the AR cistrome without major changes in the H3K4me1 landscape. npg ERG induces robust transcriptome in the Pten-loss background We examined ERG-induced transcriptome changes in prostates from 4-month-old R26 ERG mice and Pb-Cre4-negative littermate controls and found that only 20 genes changed by 1.5-fold with a false discovery rate (FDR) cutoff of <0.3, as determined by volcano plot (including a 16-fold increase in ERG transgene-linked eGFP) ( Supplementary  Fig. 15a and Supplementary Table 3 ).
However, in the Pten flox/flox background, ERG expression induced robust transcriptome changes, with more than 800 genes being significantly changed using the same criteria ( Supplementary Fig. 15b and Supplementary Table 4 ). Principal component analysis of the four groups of mice showed that the first component was determined by Pten status, and the second component was determined by ERG status (Fig. 4a) . Unsupervised hierarchical clustering showed that Pten flox/flox prostates can be clearly distinguished by ERG status. Pten-intact prostates also clustered by ERG status, although less robustly, which is consistent with subtle transcriptome alterations (Fig. 4b) . Closer examination of ERGinduced gene expression changes in the Pten WT compared to Pten flox/flox background revealed that ERG generally induced the same directional transcriptome changes, which were greatly amplified in magnitude by Pten loss (Fig. 4a,b) . In Pten flox/flox prostates, both ERG-upregulated and ERGdownregulated genes were enriched with ERG and AR peaks ( Supplementary Fig. 16a,b ). When we divided the genes into those with only AR peaks, only ERG peaks or both, only those with both types of peaks were significantly (P < 10 −14 for upregulated genes, P < 10 −10 downregulated genes) enriched for regulation by ERG ( Supplementary Fig. 16c-e ). Among genes with AR peaks, those with 'old' pre-existing AR peaks and those with new peaks found only in the setting of ERG expression were both enriched ( Supplementary Fig.  16f,g) . These data suggest that AR binding facilitates ERG-mediated transcriptional regulation. ERG-mediated upregulation of gene expression was also associated with increasing and widening of the profile of histone H3 Lys4 trimethylation (H3K4me3), a chromatin mark that is associated with active transcription 31 , toward the gene body, whereas ERG-mediated downregulation was associated with narrowing and decreasing of the H3K4me3 peak (Supplementary Fig. 17a) .
To IRAK4  PRKAR2B  BCL2L13  BID  TNFSF10  CADM1  PGLYRP1   LOC100044702  S100A8  PLAT  CXCL15  CORO1A  S100A9  FCGR3  SEMA3F  FPR2  CXCR4  CCL6  IL1B  NAV1  CCL7  CSF3R  HIF1A  CXCR2 ERG- prostate cancer, we used gene-set enrichment analysis (GSEA) 32 ( Supplementary Table 5 ). Two ERG-related human gene sets, one defined by genes upregulated in ERG-positive compared to ERGnegative human prostate cancer samples 33 and another defined by genes downregulated after ERG knockdown in VCAP cells 16 , were highly enriched (Fig. 4c) . We obtained further evidence in support of the human relevance of the model from examination of specific genes, such as AMPD3 (adenosine monophosphate deaminase 3), which is upregulated in both human and mouse ERG-positive prostate cancers. Conversely, TFF3 (trefoil factor 3) (ref. 34 ) is highly expressed in ERG-negative human prostate cancer and Pten flox/flox mouse prostates and is downregulated in ERG-positive human and Pten flox/flox ; R26 ERG mouse prostate tumors ( Fig. 4d and Supplementary Fig. 17b) .
The transcriptome heat map revealed six distinct blocks of genes whose expression patterns varied as a group across genotypes. Two groups can be defined primarily by genes upregulated by Pten loss (P up ), with one being downregulated by ERG (P up /E down ) and the other being further upregulated by ERG (P up /E up ). Similarly, there are two groups defined primarily by genes downregulated by Pten loss (P down ), with one being further downregulated by ERG (P down /E down ) and the other being upregulated by ERG (P down /E up ). Two additional groups of genes unchanged by Pten loss are defined primarily by upregulation or downregulation by ERG (E up or E down ). To understand the functional consequences of ERG expression, we performed pathway analysis of these distinct groups of genes using Ingenuity Pathway Analysis (IPA) and DAVID GO 35 (Supplementary Tables 6  and 7) . Among the most enriched processes in these groups were cell death (P up /E down ), inflammation and migration (P up /E up ) and angiogenesis (E up ) (Fig. 4e) . The identification of migration but not proliferation pathways is consistent with our histological evidence that ERG induces invasion without a change in Ki67 staining. This finding regarding cell death agrees with previous work suggesting that Pten loss induces oncogenic stress 36 , which may be alleviated by ERG expression.
ERG restores the AR transcriptome in PTEN-loss prostate cancers
Having demonstrated that ERG induces marked changes in the AR cistrome, we then investigated whether this resulted in changes in the AR transcriptome. GSEA revealed that two gene sets, one defined by genes downregulated in mouse prostates after castration and another defined by genes induced by androgen in ERG-positive VCAP cells, were highly enriched by ERG expression in the Pten flox/flox background (Fig. 5a) . As we expected on the basis of previous work, Pten loss resulted in decreased expression of AR-regulated genes, as was determined in castration experiments 9, 37 . ERG expression had no significant effect on AR target genes in Pten-intact mice but significantly restored AR transcriptional output in the setting of Pten loss (Fig. 5b,c) . As AR may regulate a distinct transcriptome in the setting of Pten loss, we performed a castration experiment in Pten flox/flox and Pten flox/flox ; R26 ERG mice (Supplementary Fig. 18 ). Expression profiling of the prostates from the four groups of mice showed that genes downregulated by castration in the setting of Pten loss are upregulated by ERG expression, including established AR target genes such as Pbsn (probasin), Nkx3-1 and Msmb (β-microseminoprotein), all of which also correlate with the H3K4me3 profile that marks active transcription (Supplementary Fig. 19) .
To determine the interaction of Pten loss and ETS expression in human prostate cancers, we used two large-scale human prostate cancer gene expression data sets, one from the University of Michigan rapid autopsy series and one from the MSKCC prostatectomy npg series 7, 33 . In both data sets, tumors with PTEN loss had a significantly (P < 0.001) decreased AR signature, consistent with previous reports. Further, in the setting of PTEN loss, ETS-positive tumors showed partial restoration of the AR signature ( Fig. 5d) . Thus, these analyses corroborate with experimental data that ETS overexpression positively regulates the AR transcriptome in prostate cancer with PTEN loss.
ETV1 modifies the AR cistrome and AR transcriptional activity
We next investigated whether the effects of ERG on AR DNA binding and transcriptional output that we found here are present with other ETS family proteins targeted by prostate cancer translocations. The LNCaP prostate cancer cell line harbors an ETV1 translocation and PTEN loss 11 . We performed ETV1 ChIP-seq in LNCaP cells and compared the binding sites that we found with those in published ERG ChIP-seq data in VCAP cells 21 . The ETV1 and ERG binding sites were highly similar, as 91% of ETV1 sites in LNCaP cells were bound by ERG in VCAP cells ( Fig. 6a , and see additional examples in Fig. 3a and Supplementary Figs. 7 and 8) . Next we examined the role of ETV1 in AR binding by performing AR ChIPseq in LNCaP cells expressing an ETV1-specific shRNA (ETV1sh2) or a scrambled control shRNA 38 . ETV1 knockdown resulted in a ~90% decrease in the number of AR binding peaks (Fig. 6b,c and Supplementary Fig. 20) . We validated this result by independent ChIP-qPCR experiments of the PSA and TMPRSS2 enhancers with two different ETV1 shRNAs and in the presence or absence of R1881 treatment (Supplementary Fig. 21) .
To determine the role of ETV1 in the AR transcriptome, we performed transcriptional profiling of ETV1 knockdown using two shRNAs. ETV1 knockdown reduced AR transcriptional activity, as measured by both AR output score and GSEA, which showed that the AR signature is the most enriched gene set ( Fig. 6d,e,  Supplementary Fig. 22 and Supplementary Table 8 ). Thus, both ETV1 and ERG positively regulate AR binding and AR transcription in the context of PTEN loss.
DISCUSSION
Previous transgenic models, although crucial in establishing the oncogenic potential of ERG, are limited by the subtle phenotype and variable penetrance. Here we report a new ERG knock-in model with uniform transgene expression in all prostate epithelial cells that results in highly predictable, early onset invasive prostate cancer when combined with Pten deficiency. These characteristics make this a broadly useful new model for the prostate cancer research community in mechanistic and therapeutic studies of ERG-driven prostate cancer.
An unanticipated finding was that ERG seems to function as a pioneer factor, causing marked changes in the AR cistrome. This property is not unique to ERG, as knockdown of ETV1 results in a similarly substantial loss in AR binding sites. The large increase in AR binding sites in ERG-expressing mice cannot be explained solely by corecruitment of AR by ERG to adjacent binding sites. However, the fact that ~80% of the new AR sites mapped to genes that also contain ERG sites supports a pioneer model in which ERG causes local chromatin changes that facilitate AR binding to nearby but not adjacent sites. Using ChIP-seq studies of the H3K4me1 enhancer mark in prostate tissue from WT mice, we established that ERG binds primarily to predefined enhancers, presumably established during development of the genitourinary tract.
At the transcriptional level, the primary consequence of the ERGdriven changes in the AR cistrome is an increase in AR output, which is particularly evident in Pten-deficient mice and PTEN-negative human tumors. This requirement for additional signaling input to enhance the transcriptional effects of ERG is reminiscent of earlier work on the related ETS family protein ETV1 showing that KIT kinase activity amplifies ETV1 transcriptional output in gastrointestinal stromal tumors 38 .
Our conclusion that ERG enhances AR function contrasts with previous work showing that ERG suppresses AR function 21, 22 . Potential explanations for these apparently contradictory findings include the fact that the earlier studies were conducted in VCAP cells, which are PTEN intact and may therefore be less 'sensitized' to the effect of ERG on the AR transcriptome. Even in VCAP cells, there is evidence that ERG serves as a pioneer factor at a number of sites for AR binding, including at the SOX9 gene 39 . Further, ERG expression may impair differentiation, which can manifest as reduced expression of classic AR target genes that are associated with terminal prostate differentiation. Further work that comprehensively assesses the AR transcriptome in various contexts should clarify this.
In summary, ERG and ETV1 mediate context-dependent oncogenic transformation by influencing the prostate lineage-specific master regulator, AR, and priming the prostate epithelium to cooperate with aberrant upstream signaling in prostate oncogenesis. On the basis of the increasing number of mutant transcription factors and chromatin modifiers emerging from cancer genome sequencing efforts, we speculate that the mechanism of oncogenesis described here for prostate cancer may be generalizable to other cancer types. 
